The Schleswig-Holstein Vasculitis Registry for the very first time enables the reliable, prospective determination of the incidence of PSV in Germany and is the largest population-based study to date around the epidemiology of vasculitides. Methods Study area and study population The study area is the state of Schleswig-Holstein, which has 2.83 million inhabitants (table 1). includes Wegeners granulomatosis [WG], microscopic polyangiitis [MPA], and Churg-Strauss syndrome [CSS]) was between 9.5 and 16 cases per million per year. WG consistently accounted for two-thirds to three-quarters of all new cases of AAV diagnosed each year. Conversation This population-based vasculitis registry designed to capture all new cases of PSV in an eight-year period Rhein (Monorhein) in a northern German region with 2.83 million inhabitants revealed stable incidence figures for all types of PSV and for AAV. Compared to figures obtained in other studies from small regions or referral centers, the incidence rate of WG (as an illustrative type of AAV) in this study was the same as those in Norway and Sweden, lower than that in the United Kingdom, but higher than those in Spain and in Vilnius (Lithuania). It is unclear whether these differences truly reflect a north-south gradient within Europe or are merely due to methodological differences. strong class=”kwd-title” Keywords: epidemiology, main systemic vasculitides, ANCA-associated vasculitides, Wegeners granulomatosis Main systemic vasculitides (PSV) are very rare diseases whose epidemiological characteristics have not yet been extensively analyzed, with the exception of arteritis (1C5). Most vasculitides have risen in incidence in recent years, particularly giant cell arteritis (GCA) (6). A number of groups have found an increased incidence of Wegeners granulomatosis (WG), microscopic polyangiitis (MPA), and Churg-Strauss syndrome (CSS) since the mid-1980s. This obtaining was associated with the discovery of the anti-neutrophilic cytoplasmic antibody (ANCA) and the acknowledgement of its diagnostic importance (7, 8). Thus, a retrospective study in Sweden revealed a significant increase in the incidence of WG from 0.77 new cases per million inhabitants per year in 1975 to 11.9 in 2001 (9). Statistics from the United Kingdom and Spain, however, for the time periods 1988 to 1998 and 1988 to 2001, respectively, have shown practically unchanged incidences for ANCA-associated vasculitides (AAV) (1, 4, 10). The case registries that have existed until now could often be faulted for being limited to a small, and thus perhaps unrepresentative, target region with a small populace, or for referral bias due to monocentric registration (1C5). This situation motivated the creation of a vasculitis registry in northern and southern Germany, from 1998 onward, within the framework of the BMBF-sponsored joint project “Vasculitides: Their Etiology, Pathogenesis, Treatment, and Epidemiology.” All newly diagnosed main systemic vasculitides, as defined by the Chapel Hill Consensus Conference, were registered from January 1, 1998, onward in a population-based study with nearly five million persons inhabiting the catchment area NOTCH4 (11). The first two years results showed no difference between northern and southern Germany in the incidence either of main systemic vasculitides overall, or of any of the individual Rhein (Monorhein) diseases in this class (12). As two years was too short a time to collect reliable, population-based epidemiological data on rare diseases, the vasculitis registry was kept in operation in the northern German federal state of Schleswig-Holstein (populace 2.83 million). An initial report was published with data from your first Rhein (Monorhein) five years (13). The goal of the present study is usually to analyze the results from a total of eight years, from 1998 to 2005, with special emphasis on ANCA-associated vasculitides. The Schleswig-Holstein Vasculitis Registry for the first time enables the reliable, prospective determination of the incidence of PSV in Germany and is the largest population-based study to date around the epidemiology of vasculitides. Methods Study area and study populace The study area is the state of Schleswig-Holstein, which has 2.83 million inhabitants (table 1). The calculated incidences are based on the population figures of January 1, 2000, and on the updated figures of January 1, 2003 (Statistical Office of the state of Schleswig-Holstein). There was relatively little populace switch attributable to immigration and emigration, the rates of which were 6% and 7%, respectively; for persons aged 50 and above, these rates were even lower (2% and 3%). Table 1 Study area and study population of the Northern German Vasculitis Registry (federal state of Schleswig-Holstein) thead th valign=”top” rowspan=”1″ colspan=”1″ /th th align=”center” valign=”top” rowspan=”1″ colspan=”1″ 1. 1. 2000 /th th align=”center” valign=”top” rowspan=”1″ colspan=”1″ 1. 1. 2003 /th /thead Populace (n)2 766 0572 823 171Male/female (%)49/5149/51Age 50 years or older37%38%% of all men3435% of all women4040Medical University or college (n*1)2Hospital departments (n*1) (= 100%)122Internal medicine (n*2)62 (5%)ENT (n)14 (11%)Ophthalmology (n)2 (2%)Dermatology (n)2 (2%)Pediatrics (n)10 (8%)Orthopedics/Surgery (n)18 (15%)Gynecology (n)3 (2%)Neurology (n)6 Rhein (Monorhein) (5%)Pathology (n)5 (5%) Open in a separate windows *1 Including outpatient clinics *2 Including all subspecialties (e.g., nephrology, pulmonology, rheumatology) Study period All newly diagnosed cases of PSV in Schleswig-Holstein from January 1, 1998, to December 31, 2005, were entered into the registry. Sources Before the.